相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer
Ernest S. Han et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2013)
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
Susana M. Campos et al.
GYNECOLOGIC ONCOLOGY (2013)
Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Tina Sharma et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2013)
Targeting angiogenesis in the pathological ovary
W. Colin Duncan et al.
REPRODUCTION FERTILITY AND DEVELOPMENT (2013)
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
G. Freyer et al.
BRITISH JOURNAL OF CANCER (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Role of angiogenesis in the pathogenesis of cancer
Paulo M. Hoff et al.
CANCER TREATMENT REVIEWS (2012)
Anti-Angiogenic Approaches to Malignant Gliomas
R. Soffietti et al.
CURRENT CANCER DRUG TARGETS (2012)
Bevacizumab and ovarian cancer
Shinya Sato et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2012)
Novel targets for VEGF-independent anti-angiogenic drugs
Marco Petrillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer
Teresa Troiani et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Cediranib: a VEGF receptor tyrosine kinase inhibitor
Marina Sahade et al.
FUTURE ONCOLOGY (2012)
Ovarian low-grade serous carcinoma: A comprehensive update
Ivan Diaz-Padilla et al.
GYNECOLOGIC ONCOLOGY (2012)
Clinical trials and future potential of targeted therapy for ovarian cancer
Hiroaki Itamochi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
Bengt Sorbe et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer
Deanna Teoh et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
R. Grepin et al.
ONCOGENE (2012)
Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Results of a Phase 2 Study
Kathryn F. McGonigle et al.
CANCER (2011)
The role of targeted therapy in ovarian cancer
Susana Banerjee et al.
EUROPEAN JOURNAL OF CANCER (2011)
Lymphangiogenesis and cancer metastasis
Mahir A. A. Al-Rawi et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2011)
Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
Kazuya Kudoh et al.
GYNECOLOGIC ONCOLOGY (2011)
Overview of anti-angiogenic agents in development for ovarian cancer
Robert A. Burger
GYNECOLOGIC ONCOLOGY (2011)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Robert L. Coleman et al.
LANCET ONCOLOGY (2011)
Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect
Maria Spiliotaki et al.
LUNG CANCER (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Antiangiogenic Therapies in Epithelial Ovarian Cancer
Deanna G. K. Teoh et al.
CANCER CONTROL (2011)
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan et al.
NATURE REVIEWS CANCER (2011)
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Robert J. Kurman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma
Hanan AlSaeid Alshenawy
ANNALS OF DIAGNOSTIC PATHOLOGY (2010)
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
A. du Bois et al.
ANNALS OF ONCOLOGY (2010)
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling
Noriomi Matsumura et al.
CANCER SCIENCE (2010)
VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis
Luqing Zhang et al.
CELL RESEARCH (2010)
FGFR2 mutations are rare across histologic subtypes of ovarian cancer
Sara A. Byron et al.
GYNECOLOGIC ONCOLOGY (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
Angiopoietin-2 Stimulation of Endothelial Cells Induces αvβ3 Integrin Internalization and Degradation
Markus Thomas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
Dan G. Duda et al.
ONCOLOGIST (2010)
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Paul Hamberg et al.
ONCOLOGIST (2010)
Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
Alfonso Sanchez-Munoz et al.
ONCOLOGY (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
Beverly L. Falcon et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma
Aref Agheli et al.
ANTI-CANCER DRUGS (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas
Kuan-Ting Kuo et al.
CANCER RESEARCH (2009)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
The Role of Fibroblast Growth Factors in Tumor Growth
M. Korc et al.
CURRENT CANCER DRUG TARGETS (2009)
Ovarian carcinoma pathology and genetics: recent advances
C. Blake Gilks et al.
HUMAN PATHOLOGY (2009)
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)
Gerald J. Roth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium
Hai Tao Yuan et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
Chunhua Lu et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy
Elena Favaro et al.
APMIS (2008)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Cost of care for elderly cancer patients in the United States
K. Robin Yabroff et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Angiogenesis as a strategic target for ovarian cancer therapy
Whitney A. Spannuth et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting
Kristian Pietras et al.
PLOS MEDICINE (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Aberrant fibroblast growth factor receptor signaling in bladder and other cancers
Christine L. Chaffer et al.
DIFFERENTIATION (2007)
Review: Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy
Hagop Youssoufian et al.
CLINICAL CANCER RESEARCH (2007)
Primary Fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction
Michael J. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent
Yira Bennudez et al.
GYNECOLOGIC ONCOLOGY (2007)
Amplicon profiles in ovarian serous carcinomas
Kentaro Nakayama et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Robert Roskoski
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
p53: Guardian of the genome and policeman of the oncogenes
Alejo Efeyan et al.
CELL CYCLE (2007)
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
David W. Kindelberger et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies
Michael Frumovitz et al.
GYNECOLOGIC ONCOLOGY (2007)
Targeted therapy for metastatic renal cell carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth
Scott A. Gerber et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer
Brenda B. J. Hermsen et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
T. Michael Numnum et al.
GYNECOLOGIC ONCOLOGY (2006)
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts
Anthony Polverino et al.
CANCER RESEARCH (2006)
Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones
Yayun Liang et al.
ENDOCRINE-RELATED CANCER (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy
Julie D. Lamb et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2006)
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
M Shibuya et al.
EXPERIMENTAL CELL RESEARCH (2006)
Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines
IA Steele et al.
GROWTH FACTORS (2006)
Autocrine activation of PDGFRα promotes the progression of ovarian cancer
D Matei et al.
ONCOGENE (2006)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells
M Grunewald et al.
CELL (2006)
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer
AM Jubb et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
A Finch et al.
GYNECOLOGIC ONCOLOGY (2006)
FGF-dependent Notch signaling maintains the spinal cord stem zone
J Akai et al.
GENES & DEVELOPMENT (2005)
Ovarian carcinoma cells and IL-1β-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions
S Stadlmann et al.
GYNECOLOGIC ONCOLOGY (2005)
AZD2171:: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
SR Wedge et al.
CANCER RESEARCH (2005)
Ovarian cancer metastasis: Integrating insights from disparate model organisms
H Naora et al.
NATURE REVIEWS CANCER (2005)
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract
WJ Cheng et al.
NATURE MEDICINE (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
R Board et al.
DRUG RESISTANCE UPDATES (2005)
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibition
JR Merchan et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines
SM Apte et al.
GYNECOLOGIC ONCOLOGY (2004)
Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma
SM Apte et al.
CLINICAL CANCER RESEARCH (2004)
Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3′-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells
L Xu et al.
CLINICAL CANCER RESEARCH (2004)
Tissue plasminogen activator is a potent activator of PDGF-CC
L Fredriksson et al.
EMBO JOURNAL (2004)
VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma
HZ Chen et al.
GYNECOLOGIC ONCOLOGY (2004)
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
H Lassus et al.
BRITISH JOURNAL OF CANCER (2004)
Mutation of the PIK3CA gene in ovarian and breast cancer
IG Campbell et al.
CANCER RESEARCH (2004)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
Evolution of the Fgf and Fgfr gene families
N Itoh et al.
TRENDS IN GENETICS (2004)
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis
S Weis et al.
JOURNAL OF CELL BIOLOGY (2004)
Ovarian tumorigenesis - A proposed model based on morphological and molecular genetic analysis
IM Shih et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms
R Erber et al.
FASEB JOURNAL (2003)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
G Singer et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cell on the development of peritoneal metastasis
A Sako et al.
JOURNAL OF SURGICAL RESEARCH (2003)
Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer
R Salgado et al.
BRITISH JOURNAL OF CANCER (2002)
Angiogenesis in epithelian ovarian cancer
ES Bamberger et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2002)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells - Relative roles of KDR and Flt-1 receptors
SY Yang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
LM Hu et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Gene expression in epithelial ovarian carcinoma
D Matei et al.
ONCOGENE (2002)
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer
JMJ Piek et al.
JOURNAL OF PATHOLOGY (2001)
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors
R Masood et al.
BLOOD (2001)
Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer
IA Steele et al.
ONCOGENE (2001)
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
P Carmeliet et al.
NATURE MEDICINE (2001)
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway
A Papapetropoulos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female
DM Sherer et al.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2000)
分享论文
